Third World Access to Essential Medicines and the WTO General Council Decision 2003
Abstract:Following the Implementation of Paragraph 6 of the Doha Declaration on TRIPS and public health, Canada was the first developed country to amend its patent law, which resulted in Canada's Access to Medicines Regime (CAMR). The CAMR allowed manufacturers to manufacture generic drugs domestically and export them to developing countries with insufficient manufacturing capacity. This paper uses the case of Rwanda, which was the first developing country to take advantage of this legislation, in order to analyse how effective the CAMR and the Paragraph 6 Agreement were in ensuring that developing countries could access generic drugs.
Document Type: Research Article
Publication date: February 1, 2010
More about this publication?
- Until 2007 the King's Law Journal was known as the King's College Law Journal. It was established in 1990 as a legal periodical publishing scholarly and authoritative Articles, Notes and Reports on legal issues of current importance to both academic research and legal practice. It has a national and international readership, and publishes refereed contributions from authors across the United Kingdom, from continental Europe and further afield (particularly Commonwealth countries and USA). The journal includes a Reviews section containing critical notices of recently published books.